Update Antiemese - Literaturverzeichnis

Supportivtherapie in der Onkologie 

Veröffentlicht am: 12.01.2024

Jürgen Barth, Gießen

Hier finden Sie das vollständige Literaturverzeichnis zum Beitrag von Dr. Jürgen Barth, Gießen "Update Antiemese" aus der Arzneimitteltherapie 1/24.

1. Aapro M. CINV: still troubling patients after all these years. Support Care Cancer 2018;26(Suppl 1):5–9.

2. Aapro M, et al. Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: Results of the nausea/emesis registry in oncology (NERO). Eur J Cancer 2022;166:126–33.

3. Aapro M, et al. Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: A quantitative market research-based survey. Cancer Rep (Hoboken) 2018;1:e1127.

4. Aapro M, et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 2012;23:1986–92.

5. Aapro MS, Walko CM. Aprepitant: drug-drug interactions in perspective. Ann Oncol 2010;21:2316–23.

6. Aapro MS, Alberts DS. High-dose dexamethasone for prevention of cis-platin-induced vomiting. Cancer Chemother Pharmacol 1981;7:11–4.

7. Andrews PLR. The mechanism of emesis induced by chemotherapy and radiotherapy. In: Tonato, M, editor. Antiemetics in the supportive care of cancer patients. Berlin, Heidelberg: Springer, 1996.

8. Antonarakis ES, Hain RD. Nausea and vomiting associated with cancer chemotherapy: drug management in theory and in practice. Arch Dis Child, 2004;89:877–80.

9. Barth J. Immunagonistische Antikörper – Pharmakologie und Management von irAEs. Krankenhauspharmazie 2016;37:333–44.

10. Bayo J, et al. Chemotherapy-induced nausea and vomiting: pathophysiology and therapeutic principles. Clin Transl Oncol 2012;14:413–22.

11. Bloechl-Daum B, et al. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006;24:4472–8.

12. Carelle N, et al. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002;95:155–63.

13. Carpenter DO, Briggs DB, Strominger N. Responses of neurons of canine area postrema to neurotransmitters and peptides. Cell Mol Neurobiol 1983;3:113–26.

14. Chambord J, et al. Ifosfamide-induced encephalopathy: Brand-name (HOLOXAN®) vs generic formulation (IFOSFAMIDE EG®). J Clin Pharm Ther 2019;44:372–80.

15. Chari A, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 2019;381:727–38.

16. Clark-Snow R, Affronti ML, Rittenberg C. Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses. Support Care Cancer 2018;26:557–64.

17. Coates A, et al. On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19:203–8.

18. Cohen R, et al. Intestinal obstruction in pregnancy by ondansetron. Reprod Toxicol 2014;50:152–3.

19. de Boer-Dennert M, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 1997;76:1055–61.

20. Dielenseger P, et al. Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey. Support Care Cancer 2019;27:4099–106.

21. Drugdex®: Ondansetron. 2023.

22. Durand JP, et al. Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy. Ann Oncol 2007;18:808–9.

23. Eisenberg P, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003;98:2473–82.

24. EMA. Aprepitant Procedure No. EMEA/H/C/000527/PSUV/0042 2013. https://www.ema.europa.eu/en/documents/scientific-conclusion/emend-h-c-527-psuv-0042-epar-scientific-conclusions-grounds-recommending-variation-terms-marketing_en.pdf (Zugriff am 13.10.2023).

25. EMEA. Ifosfamide-containing solutions - EMEA-H-A-31-1495. 2021 cited 2023. https://www.ema.europa.eu/en/documents/referral/ifosfamide-solutions-article-31-referral-annex-ii_de.pdf (Zugriff am 13.10.2023).

26. FDA. FDA Drug Safety Communication: Abnormal heart rhythms may be associated with use of Zofran (ondansetron). 2011. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-abnormal-heart-rhythms-may-be-associated-use-zofran-ondansetron (Zugriff am 13.10.2023).

27. Fejzo MS, MacGibbon K, Mullin P. Intestinal obstruction is a rare complication of ondansetron exposure in hyperemesis gravidarum. Reprod Toxicol 2015;57:207.

28. Gangireddy M. Ifosfamide (Updated 2023 Mar 2). In: StatPearls (Internet). 2023, StatPearls Publishing: Treasure Island (FL).

29. Goodman LS, Wintrobe MM, et al. Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin‘s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J Am Med Assoc 1946;132:126–32.

30. Gralla RJ, et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981;305:905–9.

31. Griffin AM, et al. On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993 Ann Oncol 1996;7:189–95.

32. Grunberg, S. Patient-centered management of chemotherapy-induced nausea and vomiting. Cancer Control 2012;19:10–5.

33. GSK. Informationsbrief zu Zofran® (Ondansetron) 14.08.2012. https://www.akdae.de/fileadmin/user_upload/akdae/Arzneimittelsicherheit/Weitere/Archiv/2012/20120803.pdf (Zugriff am 13.10.2023).

34. GSK. Wichtige Informationen für Fachkreise zu Ondansetron 16.07.2013. https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/EN/RHB/2013/info-zofran.pdf?__blob=publicationFile (Zugriff am 13.10.2023).

35. Hanser H, Scholtyssek C. Brechzentrum. Lexikon der Neurowissenschaft 2000 cited 2023. https://www.spektrum.de/lexikon/neurowissenschaft/#/suche/q/brechzentrum (Zugriff am 13.10.2023).

36. Harten P. Fibromyalgia syndrome: new developments in pharmacotherapy. Z Rheumatol 2008;67:75–82.

37. Hashimoto H, et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21:242–9.

38. Helsinn Birex Pharmaceuticals Ltd., D.M., Dublin 15 Irland (2018) Aloxi® 250 Mikrogramm Injektionslösung. www.ema.europa.eu/en/documents/product-information/akynzeo-epar-product-information_de.pdf (Zugriff am 13.10.2023).

39. Helsinn_Birex_Pharmaceuticals_Ltd, Fachinformation Akynzeo. 2022. https://www.ema.europa.eu/en/documents/product-information/akynzeo-epar-product-information_de.pdf (Zugriff am 13.10.2023).

40. Hernandez Torres C, et al. Defining optimal control of chemotherapy-induced nausea and vomiting-based on patients‘ experience. Support Care Cancer 2015;23:3341–59.

41. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008;358:2482–94.

42. Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020;38:2782–97.

43. Hesketh PJ. Pathophysiology and prediction of chemotherapy-induced nausea and vomiting 2023; Wolters Kluwer UpToDate. 2023. https://www.uptodate.com/contents/pathophysiology-and-prediction-of-chemotherapy-induced-nausea-and-vomiting#! (Zugriff am 13.10.2023).

44. Hillaire-Buys D, et al. Liquid formulation of ifosfamide increased risk of encephalopathy: A case-control study in a pediatric population. Therapie 2019;75:471–80.

45. Hofman M, et al. Cancer patients’ expectations of experiencing treatment-related side effects: a University of Rochester Cancer Center-Community Clinical Oncology Program study of 938 patients from community practices. Cancer 2004;101:851–7.

46. Howell JE, et al. Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant. J Oncol Pharm Pract 2008;14:157–62.

47. Institut Claudius Regaud. Pharmacologic interaction between Ifosfamide and Aprepitant in treated patients with soft tissue sarcoma (IPIAP-STM). ClinicalTrials.gov Identifier: NCT03514381. 2023, United States National Library of Medicine.

48. Jahn F, et al. The prevention and treatment of nausea and vomiting during tumor therapy. Dtsch Arztebl Int 2022;119:382–92.

49. Janelsins MC, et al. Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother 2013;14:757–66.

50. Jarkowski A, Miller A, Hecke TA, et al. The risk of neurotoxicity with concomitant use of aprepitant and ifosfamide. J Hematol Oncol Pharm 2011;1:16–21.

51. Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 2015;26:1081–90.

52. Jordan K, Scholl HJ, Aapro MS. Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol 2007;61:162–75.

53. Jordan K, Jahn F, Feyer P, Karthaus M, et al. Onkopedia-Leitlinie Antiemese bei medikamentöser Tumortherapie Stand Mai 2021. https://www.onkopedia.com/de/onkopedia/guidelines/antiemese-bei-medikamentoeser-tumortherapie/@@guideline/html/index.html (Zugriff am 13.10.2023).

54. Kamen C, et al. Anticipatory nausea and vomiting due to chemotherapy. Eur J Pharmacol 2014;722:172–9.

55. Kataria PS, Kendre PP, Patel AA. Ifosfamide-induced encephalopathy precipitated by aprepitant: A rarely manifested side effect of drug interaction. J Pharmacol Pharmacother 2017;8:38–40.

56. Kim H, et al. Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11). Cancer 2022;128:778–87.

57. Kim MS, et al. Association of 5-HT3B receptor gene polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting. Yonsei Med J 2015;56:1415–20.

58. Kris MG, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 2006;24:2932–47.

59. Kris MG, et al. Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. Cancer 1985;55:527–34.

60. Kyowa Kirin International NewCo Germany GmbH. Fachinformation SANCUSO® 3,1 mg/24 Stunden transdermales Pflaster, 2020.

61. Lievense LA, et al. Clinical outcomes of patients with metastatic NSCLC after discontinuation of immunotherapy because of immune-related adverse effects. JTO Clin Res Rep 2023;4:100441.

62. Lindley C, et al. Perception of chemotherapy side effects cancer versus noncancer patients. Cancer Pract 1999;7:59–65.

63. Lumitos AG. Metoclopramid. https://www.chemie.de/lexikon/Metoclopramid.html (Zugriff am 13.10.2023).

64. Martin M. The severity and pattern of emesis following different cytotoxic agents. Oncology 1996;53: 26–31.

65. McCrea JB, et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003;74:17–24.

66. Morrow GR, et al. Progress in reducing anticipatory nausea and vomiting: a study of community practice. Support Care Cancer 1998;6:46–50.

67. Merck Sharp & Dohme B.V. Fachinformation Emend 2020.

68. Mustian KM, et al. Chemotherapy-induced nausea and vomiting. US Oncol 2008;4:19–23.

69. Naik RD, et al. Olanzapine for prevention of vomiting in children and adolescents receiving highly emetogenic chemotherapy: investigator-initiated, randomized, open-label trial. J Clin Oncol 2020;38:3785–93.

70. National Cancer Institute. Anticipatory nausea and vomiting. Nausea and vomiting related to cancer treatment (PDQ®)–Health Professional Version 2023. https://www.cancer.gov/about-cancer/treatment/side-effects/nausea/nausea-hp-pdq#_20 (Zugriff am 16.10.2023).

71. Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 2016;374:1356–67.

72. Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer, 2013;21:1655–63.

73. National Comprehensive Cancer Network®. Antiemesis. NCCN Guidelines - Supportive Care 2.2023. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf (Zugriff am 16.10.2023).

74. Needleman R. Chemotherapy: An overview of nausea and vomiting in the cancer patient: etiology and management of serious complications of chemotherapy. AAOHN J, 1987;35:179–82.

75. Olver IN, et al. Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor hemotherapy. Support Care Cancer 2013;21:1561–8.

75a. Ostwal SV, et al. Olanzapine for the prevention of chemotherapy induced nausea vomiting in patients receiving moderately emetogenic chemotherapeutic (MEC) regimens: Results of a prospective triple blinded phase III multicentric study (OMEC). ESMO Congress 2023. Presentation Number LBA97. https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/show/session/61.

76. Patel P, et al. Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol 2017;83:2148–62.

77. Pirl WF, Roth AJ. Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report. Psychooncology 2000;9:84–7.

78. Rao KV, Faso A. Chemotherapy-induced nausea and vomiting: optimizing prevention and management. Am Health Drug Benefits 2012;5:232–40.

79. Roeland EJ, et al. What the HEC? Clinician adherence to evidence-based antiemetic prophylaxis for highly emetogenic chemotherapy. J Natl Compr Canc Netw 2020;18:676–81.

80. Roila F, et al. Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1987;5:141–9.

81. Roila F, Molassiotis A, Herrstedt J, Aapro M, et al. MASCC and ESMO guideline update for the prevention of chemotherapy and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016;27(Supplement 5):119–33.

82. Saito M, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009;10:115–24.

83. Sanofi Aventis. Rote-Hand-Brief zu Anemet® 100 mg i. v. (20 mg/ml Injektionslösung) 2011. https://www.akdae.de/fileadmin/user_upload/akdae/Arzneimittelsicherheit/RHB/Archiv/2011/20110210.pdf (Zugriff am 16.10.2023).

84. Schoffelen R, et al. Drug-drug interactions with aprepitant in antiemetic prophylaxis for chemotherapy. Neth J Med 2018;76:109–14.

85. Sejourne A, et al. Two cases of fatal encephalopathy related to Ifosfamide: an adverse role of aprepitant? Case Rep Oncol 2014;7:669–72.

86. Shindorf ML, Manahan KJ, Geisler JP. The interaction of ifosfamide and aprepitant in gynecologic malignancies. Gynecol Oncol Case Rep 2013;6:34–5.

87. Sridhar KS, Donnelly E. Combination antiemetics for cisplatin chemotherapy. Cancer 1988;61:1508–17.

88. Stratz T, et al. Fibromyalgia treatment with intravenous tropisetron administration. Drugs Exp Clin Res 2001;27:113–8.

89. Sun CC, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 2005;13:219–27.

90. Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF. S3-Leitlinie Supportive Therapie bei onkologischen PatientInnen Langversion 1.3. Februar 2020.

91. Szabatura AH, et al. An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center. J Oncol Pharm Pract 2015:21:188–93.

92. Tzeng A, Tzeng TH, Ornstein MC. Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis. J Immunother Cancer 2021;9(10):e003473.

93. Wolters Kluwer. UpToDate® 2023. Characteristics of antiemetic drugs. Ondansetron/Granisetron//Palonosetron/Olanzapin/Aprepitant/Netupitant: Drug Information.

94. Vardy J, et al. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 2006;94:1011–5.

95. Vazirian, F. et al. Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review. Cancer Chemother Pharmacol 2022;90:1–6.

96. Vidall, C, et al. Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey. Support Care Cancer 2015;23:3297–305.

97. Wei AH, et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med 2020;383:2526–37.

98. Zoto T, et al. Improved anti-emetic efficacy of 5-HT3 receptor antagonists in cancer patients with genetic polymorphisms of ABCB1 (MDR1) drug transporter. Basic Clin Pharmacol Toxicol 2015;116:354–60.


1 Conundrum, engl.: Rätsel, auch fig.: schwierige Frage, unlösbares Problem

* Modifizierter Nachdruck aus Medizinische Monatsschrift für Pharmazeuten 2023;46:428–51.


Jürgen Barth, StiL-Studienzentrale, Med. Klinik IV, Universitätsklinikum Gießen, Klinikstraße 36, 35385 Gießen, E-Mail: Juergen.Barth@innere.med.uni-giessen.de

Erhalten Sie jetzt uneingeschränkten Zugriff auf:
  • Alle Fachartikel in der AMT
  • Regelmäßige zertifizierte Fortbildungen
  • Aktuelle Informationen zu neuen Arzneimitteln – von Experten kommentiert
Mehr erfahren